MX2019015350A - Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de la fibrosis. - Google Patents

Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de la fibrosis.

Info

Publication number
MX2019015350A
MX2019015350A MX2019015350A MX2019015350A MX2019015350A MX 2019015350 A MX2019015350 A MX 2019015350A MX 2019015350 A MX2019015350 A MX 2019015350A MX 2019015350 A MX2019015350 A MX 2019015350A MX 2019015350 A MX2019015350 A MX 2019015350A
Authority
MX
Mexico
Prior art keywords
diseases
treatment
pharmaceutical compositions
fibrosis
novel compounds
Prior art date
Application number
MX2019015350A
Other languages
English (en)
Inventor
Jeanne Marie Menet Christel
Mammoliti Oscar
Laurent Brebion Franck
Allart Brigitte
Alessandro TRICARICO Giovanni
Duthion Béranger
Karel Jansen Koen
Marie Elise Palisse Adeline
El Bkassiny Sandy
Patrick Claude Jaunet Alexis
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2019015350A publication Critical patent/MX2019015350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos de acuerdo con la Fórmula I; en donde R1, R2, L, A1, A2, A3, Cy y el subíndice n son como se definen en la presente. La presente invención se relaciona con compuestos antagonistas de los receptores de esfingosina 1-fosfato (S1P), con métodos para su producción, con composiciones farmacéuticas que los comprenden y con métodos de tratamiento que los usan, para la profilaxis y/o el tratamiento de enfermedades que comprenden enfermedades fibróticas, enfermedades inflamatorias, enfermedades respiratorias, enfermedades autoinmunes, enfermedades metabólicas, enfermedades cardiovasculares y/o enfermedades proliferativas, mediante la administración del compuesto de la invención.
MX2019015350A 2017-07-06 2018-06-21 Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de la fibrosis. MX2019015350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1710851.5A GB201710851D0 (en) 2017-07-06 2017-07-06 Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
PCT/EP2018/066548 WO2019007696A1 (en) 2017-07-06 2018-06-21 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS

Publications (1)

Publication Number Publication Date
MX2019015350A true MX2019015350A (es) 2020-02-20

Family

ID=59676764

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015350A MX2019015350A (es) 2017-07-06 2018-06-21 Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de la fibrosis.

Country Status (18)

Country Link
US (1) US20210315893A1 (es)
EP (1) EP3649119B1 (es)
JP (1) JP2020525508A (es)
KR (1) KR20200027543A (es)
CN (1) CN110869359A (es)
AR (1) AR112264A1 (es)
AU (1) AU2018296398A1 (es)
BR (1) BR112020000029A2 (es)
CA (1) CA3069038A1 (es)
CO (1) CO2020000056A2 (es)
GB (1) GB201710851D0 (es)
IL (1) IL271807A (es)
MA (1) MA52118A (es)
MX (1) MX2019015350A (es)
RU (1) RU2020105248A (es)
SG (1) SG11202000032PA (es)
TW (1) TW201920167A (es)
WO (1) WO2019007696A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200094734A (ko) 2017-09-22 2020-08-07 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 헤테로사이클릭 화합물
DK3697785T3 (da) 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidazo-pyridine forbindelser som pad-inhibitorer
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
CA3083374A1 (en) 2017-11-24 2019-05-31 Jubilant Episcribe Llc Heterocyclic compounds as prmt5 inhibitors
AU2019234185A1 (en) 2018-03-13 2020-10-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
JP2022537059A (ja) * 2019-06-21 2022-08-23 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド アロステリックｅｇｆｒ阻害剤及びその使用方法
JP7307282B2 (ja) * 2020-03-04 2023-07-11 ヒーリオイースト ファーマシューティカル カンパニー リミテッド ベンゾ２－アザスピロ［４．４］ノナン系化合物及びその使用
IL300289A (en) * 2020-08-14 2023-04-01 Denali Therapeutics Inc Compounds, preparations and methods
EP3974415A1 (en) 2020-09-24 2022-03-30 Janssen Pharmaceutica NV Nlrp3 modulators
CN113234024A (zh) * 2021-05-20 2021-08-10 北京迈索化学技术有限公司 一种奥拉帕利的制备新方法
CN113929689B (zh) * 2021-11-02 2022-09-27 济南悟通生物科技有限公司 一种鲁卡帕利关键中间体的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919331B2 (en) * 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
BRPI0808422A2 (pt) * 2007-03-06 2015-06-23 Novartis Ag Compostos orgânicos bicíclicos adequados para o tratamento de condições inflamatórias ou alérgicas
US8012992B2 (en) * 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
US8436016B2 (en) * 2008-10-23 2013-05-07 Scott D. Kuduk Fused heterocyclic M1 receptor positive allosteric modulators
JP5819831B2 (ja) * 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
WO2011146882A1 (en) * 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
DK2835131T3 (en) * 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
US8969363B2 (en) * 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AR091790A1 (es) * 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN105102000B (zh) * 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
AR094797A1 (es) * 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
KR102231637B1 (ko) 2013-03-14 2021-03-25 갈라파고스 엔.브이. 염증 질환의 치료를 위한 화합물 및 그의 약학 조성물

Also Published As

Publication number Publication date
AR112264A1 (es) 2019-10-09
SG11202000032PA (en) 2020-02-27
CN110869359A (zh) 2020-03-06
RU2020105248A (ru) 2021-08-06
WO2019007696A1 (en) 2019-01-10
TW201920167A (zh) 2019-06-01
JP2020525508A (ja) 2020-08-27
IL271807A (en) 2020-02-27
EP3649119B1 (en) 2021-11-03
CO2020000056A2 (es) 2020-01-17
US20210315893A1 (en) 2021-10-14
EP3649119A1 (en) 2020-05-13
KR20200027543A (ko) 2020-03-12
BR112020000029A2 (pt) 2020-07-14
MA52118A (fr) 2021-05-19
AU2018296398A1 (en) 2020-02-27
CA3069038A1 (en) 2019-01-10
GB201710851D0 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
MX2019015350A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de la fibrosis.
PH12018501849A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
PH12017501911A1 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
MY170260A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TN2017000009A1 (en) Spirocycloheptanes as inhibitors of rock.
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
PH12014502586A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
PH12018501644A1 (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
MX2020003863A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2013006768A (es) Moduladores de receptor de glucagon.
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
MX2017016939A (es) Novedosas antagonistas 5-ht2.
MX2021011576A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2021011574A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.